Australian ChemGenex Anticipates March Approval For First Product Omapro For Gleevec-resistant CML Patients
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Melbourne-headquartered ChemGenex will see its first product Omapro under review by U.S. FDA's Oncologic Drugs Advisory Committee Feb. 10 for patients with chronic myeloid leukemia who have failed to respond to Gleevec and who have the Bcr-Abl T315I mutation
You may also be interested in...
What Financial Crisis? Australian Biotech Enters Golden Era (Part 2 of 2)
PERTH, Australia - As Australia's biotech sector comes of age, it is beginning to attract the attention of multinational companies, as evidenced by stepped-up merger and acquisition activity and rounds of new funding in the last six months
What Financial Crisis? Australian Biotech Enters Golden Era (Part 2 of 2)
PERTH, Australia - As Australia's biotech sector comes of age, it is beginning to attract the attention of multinational companies, as evidenced by stepped-up merger and acquisition activity and rounds of new funding in the last six months
Australian ChemGenex's Omapro Faces Scaled Back Efficacy Claims After Trial Shortcomings
After a snow delay in Washington, Australian-headquartered ChemGenex now has more time to prepare for what will likely be a challenging review of Omapro (omacetaxine mepesuccinate) by U.S. FDA's Oncologic Drugs Advisory Committee